-  INCLUSION CRITERIA:

          -  For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by
             immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on
             greater than or equal to 50% of cancer cells, or greater than or equal to 1+ CD70
             positive on greater than or equal to 75% of cancer cells).

          -  For Phase II: Measurable (per RECIST v1.1 criteria), unresectable cancer expressing
             CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to
             2+ CD70 positive on greater than or equal to 50% of cancer cells, or greater than or
             equal to 1+ CD70 positive on greater than or equal to 75% of cancer cells).

          -  Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.

          -  Patients must have previously received at least one standard therapy for their cancer
             (if available) and have been either non-responders (progressive disease) or have
             recurred.

          -  Patients with 3 or fewer brain metastases that are less than or equal to 1 cm in
             diameter and asymptomatic are eligible. Lesions that have been treated with
             stereotactic radiosurgery must be clinically stable for 1 month after treatment for
             the patient to be eligible. Patients with surgically resected brain metastases are
             eligible.

          -  Age greater than or equal to 18 years and less than or equal to 70 years.

          -  Clinical performance status of ECOG 0 or 1

          -  Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for four months after treatment.

          -  Serology

               -  Seronegative for HIV antibody. (The experimental treatment being evaluated in
                  this protocol depends on an intact immune system. Patients who are HIV
                  seropositive may have decreased immune-competence and thus be less responsive to
                  the experimental

        treatment and more susceptible to its toxicities.)

          -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then patient must be tested for the presence of
             antigen by RT-PCR and be HCV RNA negative.

             -Hematology

          -  ANC greater than 1000/mm(3) without the support of filgrastim

          -  WBC greater than or equal to 3000/mm(3)

          -  Platelet count greater than or equal to 100,000/mm(3)

          -  Hemoglobin > 8.0 g/dL. Subjects may be transfused to reach this cut-off.

             -Chemistry

          -  Serum ALT/AST less than or equal to 5.0 times ULN

          -  Serum creatinine less than or equal to 1.6 mg/dL

          -  Total bilirubin less than or equal to 1.5 mg/dL, except in patients with Gilbert s
             Syndrome who must have a total bilirubin less than 3.0 mg/dL.

               -  More than four weeks must have elapsed since completion of any prior systemic
                  therapy at the time of enrollment.

        Note: Patients may have undergone minor surgical procedures or limited field radiotherapy
        within the four weeks prior to enrollment, as long as related major organ toxicities have
        recovered to grade 1 or less.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

          -  Willing to sign a durable power of attorney.

          -  Subjects must be co-enrolled on the NCI-SB cell harvest protocol 03-C-0277 (Cell
             Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).

        EXCLUSION CRITERIA:

          -  Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          -  Concurrent systemic steroid therapy.

          -  Active systemic infections requiring anti-infective treatment, coagulation disorders,
             or any other active or uncompensated major medical illnesses.

          -  Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          -  History of major organ autoimmune disease.

          -  Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased
             immune-competence may be less responsive to the experimental treatment and more
             susceptible to its toxicities).

          -  History of severe immediate hypersensitivity reaction to cyclophosphamide,
             fludarabine, or aldesleukin.

          -  History of coronary revascularization or ischemic symptoms.

          -  Documented LVEF less than or equal to 45% tested in patients:

               -  Age greater than or equal to 65 years

               -  With clinically significant atrial and/or ventricular arrhythmias, including but
                  not limited to: atrial fibrillation, ventricular tachycardia, second- or
                  third-degree heart block, or have a history of ischemic heart disease and/or
                  chest pain.

               -  Who have had prior treatment with significant exposure to anthracyclines or
                  cyclophosphamide.

          -  Documented FEV1 less than or equal to 60% predicted tested in patients with:

               -  A prolonged history of cigarette smoking (greater than or equal to 20 pack-year
                  smoking history, with cessation within the past 2 years).

               -  Symptoms of respiratory dysfunction

          -  Patients who are receiving any other investigational agents.